Dr Steven K. Libutti (Bronx, NY): No disclosures. Very interesting work, and obviously anaplastic thyroid
cancer represents a significant problem in our management of patients with thyroid
cancer. Epithelial-to-mesenchymal transition is a critical pathway in the transition
of cells to a more invasive phenotype. In alluding to some of the animal data that
you've had or looked at with this target, how druggable is this target? In terms of
thinking toward the future of designing therapies that you will be able to use to
attack this, how successful are agents so far that can be used to attack it when converted
to things you can give to mice and then hopefully humans in terms of dosing, pharmicokinetics,
et cetera?
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: November 05, 2015
Identification
Copyright
© 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
